CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in three key investor conferences in April 2022. These include the 21st Annual Needham Virtual Healthcare Conference on April 12 at 12:45 PM ET, the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14 at 1:00 PM ET, and the 14th Kempen Life Sciences Conference in Amsterdam on April 20 at 3:30 PM CET. Live webcasts will be accessible on the company's website, with a 14-day replay available post-event.
CRISPR Therapeutics focuses on gene-based medicines for serious diseases using its innovative CRISPR/Cas9 technology.
- None.
- None.
ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in April:
21st Annual Needham Virtual Healthcare Conference
Date: Tuesday, April 12, 2022
Time: 12:45 PM ET
Canaccord Genuity Horizons in Oncology Virtual Conference
Date: Thursday, April 14, 2022
Time: 1:00 PM ET
14th Kempen Life Sciences Conference Amsterdam
Date: Wednesday, April 20, 2022
Time: 3:30 PM CET
A live webcast of the Needham and Canaccord presentations will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
What investor conferences will CRISPR Therapeutics participate in April 2022?
What is the schedule for CRISPR Therapeutics' presentations in April 2022?
How can I access the webcasts of CRISPR Therapeutics' investor presentations?
What technology does CRISPR Therapeutics use in its gene-based medicines?
What is the focus area of CRISPR Therapeutics' research and development?
